What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Q2W Administered intravenously Drug: Penpulimab Q2W Administered intravenously Drug:Trifluridine and Tipiracil Hydrochloride Tablets BID,Oral Administration Drug:Bevacizumab Injection Q2W Administered intravenously”In the company’s words, NCT07387081 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor Cancer, Advanced Solid Tumor
- Main trialPhase 2
- “This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor”In the company’s words, NCT07387081 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 21 May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 21 May 2028 | Phase II Study of LM-24C5 | |
| Phase 1/2Recruiting | 30 Jun 2026 | A Study of LM-24C5 For Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026